Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy
NCT ID: NCT05251493
Last Updated: 2025-05-15
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE3
Total Enrollment
280 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-06-06
Study Completion Date
2027-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Ion deficiency anemia (IDA) is associated with poor neonatal outcomes and maternal morbidity. Iron replacement may be done with oral iron or intravenous iron, with intravenous iron being utilized later in pregnancy or if there is an inadequate response to oral iron in the first trimester. In Canada, iron sucrose has been used, however iron isomaltoside is as safe as other formulations of IV iron but can replete iron stores with a single visit. Replenishing iron stores reduces both maternal and neonatal risks and is supported by current guidelines. Iron status may play a role in depression, as well as anemia, bleeding and blood transfusion.
The goal of this clinical trial:
* Correct IDA with fewer visits and less impact on the healthcare system
* Improve the health and well being of all pregnant women who are experiencing moderate to severe iron deficiency anemia.
The goal of this clinical trial:
* Correct IDA with fewer visits and less impact on the healthcare system
* Improve the health and well being of all pregnant women who are experiencing moderate to severe iron deficiency anemia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy.
NCT03188445
Iron Deficiency Anemia of Pregnancy
COMPLETED
PHASE4
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
NCT03238911
Iron Deficiency Anaemia
Iron Deficiency Anemia
COMPLETED
PHASE3
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
NCT03237065
Iron Deficiency Anaemia
Iron Deficiency Anemia
COMPLETED
PHASE3
To Compare the Efficacy of I.V 200 mg Iron Sucrose and 500 mg Iron Sucrose to Treat Anemia in Pregnancy
NCT02441439
Pregnancy
WITHDRAWN
NA
Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy
NCT01245777
Restless Leg Syndrome
Iron Deficiency Anemia
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
IDA is associated with poor neonatal outcomes and maternal morbidity. This clinical trial will compare IV iron isomaltoside to IV iron sucrose for correction of IDA, along with the potential impacts to the patient: physical, emotional and convenience. The study will also take into consideration the financial and resource impacts to the healthcare system, as well as determine the validity of using iron isomaltoside in second and third trimester pregnancy.
The trial will be a randomized, comparative, single center, phase III trial with a 1:1 allocation ratio. There will be two groups involved in this trial. Group 1: A single dose of IV iron isomaltoside. Group 2: Standard iron sucrose therapy.
Eligible participants will be screened for IDA during the initial appointment (greater or equal to 13 weeks gestational age) with the obstetrical care provider. Discussion/awareness about the study will be discussed at their appointment or over the telephone with the obstetrical care provider. This information will only be discussed if the patient requires IV iron repletion in second or third trimester pregnancy.
Enrollment inclusion/exclusion criteria must be met for the participant to receive the information about the study.
Study personnel will discuss the clinical trial, including obtaining informed consent with the eligible participant. Baseline vital signs and blood work will be documented from the previous patient visit where IDA was diagnosed. Documentation and data collection will occur at 3 other points within the clinical trial: Post iron infusion (approximately 30 days after infusion), during delivery and at 6 weeks postpartum.
Standard community blood work requisitions will be used for blood work and blood tests that occur within the community or health clinic setting. Standard Physician orders or Pre Printed orders will be followed for tests, bloodwork and medication administration while in hospital at the delivery admission. Participant duration will be from intake (approximately 13 weeks gestation to 6 week follow up post delivery of infant). The follow up at the 6 week appointment will be the end point for the participation of the study. A total of approximately 231 days of involvement within the study duration for each participant.
The study will be completed 36 months after the enrollment of the first participant or when all patients have been recruited to satisfy the sample size calculation.
The sample size is calculated based on the primary endpoint (achievement of Hb≥110 g/L after iron intervention). As iron isomaltoside has a faster rise in hgb (weeks 1 to 5) with fewer visits, it is assumed that 5% of iron isomaltoside and 15% of iron sucrose participants will have hgb \<110 g/L at delivery. Given the 10% difference between groups of patients achieving a hgb ≥110g/L in the iron isomaltoside group, it is calculated that at a p of 0.05 and a power of 80%, 140 participants are required in each treatment group.
The primary endpoint of this trial is the correction of anemia, defined as Hgb greater or equal to 110 g/L at trial post iron infusion (30 days post iron infusion (with measured hemoglobin levels during delivery and at six weeks postpartum).
The secondary endpoint is the change in quality of life questionnaires from baseline, post iron infusion, at delivery and 6 weeks postpartum through standard Redcap tools. Additionally, any adverse event will be documented with appropriate follow up care.
Participant subjective data will also be collected based on tolerance of IV iron, pregnancy related symptoms and quality of life comparing pre iron infusion, post iron infusion, at delivery and again at 6 weeks post delivery. Participants will also be required to answer questions related to convenience of appointment for iron infusion(s), accessibility to the infusion appointments and post birth bonding with baby.
Analysis will be performed after data collection is complete using the latest version of RStudio. Qualitative variables will be expressed as counts, percentages, quantitative variables as mean +/- standard deviation or median (interquartile range \[IQR\] depending on the variable distribution. Comparison of continuous variables will be performed using the two sided Student's t test or Mann Whitney U test (where appropriate), and the chi squared test or Fisher's exact test (where appropriate) to compare category variables. The Kaplan Meier method will be used for the graphical assessment of time related events. Analysis of the primary efficacy and safety endpoints will be by intention to treat.
Participants who withdraw either due to medical condition or expressed withdrawal will be set as censored. No data relating to the withdrawal will be utilized in the data analysis. The proportion of endpoints will be analyzed using logistic regression. Continuous secondary endpoints will be analyzed by linear regression. For analyzing missing data, model based multiple imputations will be used for both primary and secondary outcomes.
Eligible pregnant women with iron deficiency will be recruited through the Department of Obstetrics and Gynecology Department, or through health care providers that maintain obstetrical care privileges at RGH.
Treatments arms will be allocated through a blocked randomization list prepared by an online tool. Moreover, the randomization will be stratified by Hgb level in increments of 10g/L to pursue equal distribution of the two groups. The sequence list will not be accessible to the investigators. Participants will be randomly assigned to receive either IV iron isomaltoside or IV iron sucrose. IV iron sucrose is the comparator because it is currently the formulation used for IDA during second and third trimester pregnancy in Regina, Saskatchewan, Canada. Products will be stored as per the product monograph and as per requirements and guidelines set out by the Saskatchewan Health Authority.
The Saskatchewan Health Authority will ensure that the written agreement to perform trial related monitoring, audits, Research Ethics Board reviews and regulatory inspections, and provide direct access to source data and/or documents of this clinical trial, as required. Data and source documents must be readily available to the Research Ethics Board, Health Canada, Therapeutic Products Directorate, inspectors, clinical trial team members, including investigators and/or obstetrical care providers for the purposes of compliance with regulatory requirements of the clinical protocol and purposes relating to treatment, care and follow up of adverse drug reactions or by means of trace back/lookback as required. Source data and documentation include patient records whether hard copy or electronic, blood work, appointment dates and times, test and procedure results relating to this clinical trial. All source documents must be accessible during the clinical trial period and after the clinical trial has completed.
The trial will be a randomized, comparative, single center, phase III trial with a 1:1 allocation ratio. There will be two groups involved in this trial. Group 1: A single dose of IV iron isomaltoside. Group 2: Standard iron sucrose therapy.
Eligible participants will be screened for IDA during the initial appointment (greater or equal to 13 weeks gestational age) with the obstetrical care provider. Discussion/awareness about the study will be discussed at their appointment or over the telephone with the obstetrical care provider. This information will only be discussed if the patient requires IV iron repletion in second or third trimester pregnancy.
Enrollment inclusion/exclusion criteria must be met for the participant to receive the information about the study.
Study personnel will discuss the clinical trial, including obtaining informed consent with the eligible participant. Baseline vital signs and blood work will be documented from the previous patient visit where IDA was diagnosed. Documentation and data collection will occur at 3 other points within the clinical trial: Post iron infusion (approximately 30 days after infusion), during delivery and at 6 weeks postpartum.
Standard community blood work requisitions will be used for blood work and blood tests that occur within the community or health clinic setting. Standard Physician orders or Pre Printed orders will be followed for tests, bloodwork and medication administration while in hospital at the delivery admission. Participant duration will be from intake (approximately 13 weeks gestation to 6 week follow up post delivery of infant). The follow up at the 6 week appointment will be the end point for the participation of the study. A total of approximately 231 days of involvement within the study duration for each participant.
The study will be completed 36 months after the enrollment of the first participant or when all patients have been recruited to satisfy the sample size calculation.
The sample size is calculated based on the primary endpoint (achievement of Hb≥110 g/L after iron intervention). As iron isomaltoside has a faster rise in hgb (weeks 1 to 5) with fewer visits, it is assumed that 5% of iron isomaltoside and 15% of iron sucrose participants will have hgb \<110 g/L at delivery. Given the 10% difference between groups of patients achieving a hgb ≥110g/L in the iron isomaltoside group, it is calculated that at a p of 0.05 and a power of 80%, 140 participants are required in each treatment group.
The primary endpoint of this trial is the correction of anemia, defined as Hgb greater or equal to 110 g/L at trial post iron infusion (30 days post iron infusion (with measured hemoglobin levels during delivery and at six weeks postpartum).
The secondary endpoint is the change in quality of life questionnaires from baseline, post iron infusion, at delivery and 6 weeks postpartum through standard Redcap tools. Additionally, any adverse event will be documented with appropriate follow up care.
Participant subjective data will also be collected based on tolerance of IV iron, pregnancy related symptoms and quality of life comparing pre iron infusion, post iron infusion, at delivery and again at 6 weeks post delivery. Participants will also be required to answer questions related to convenience of appointment for iron infusion(s), accessibility to the infusion appointments and post birth bonding with baby.
Analysis will be performed after data collection is complete using the latest version of RStudio. Qualitative variables will be expressed as counts, percentages, quantitative variables as mean +/- standard deviation or median (interquartile range \[IQR\] depending on the variable distribution. Comparison of continuous variables will be performed using the two sided Student's t test or Mann Whitney U test (where appropriate), and the chi squared test or Fisher's exact test (where appropriate) to compare category variables. The Kaplan Meier method will be used for the graphical assessment of time related events. Analysis of the primary efficacy and safety endpoints will be by intention to treat.
Participants who withdraw either due to medical condition or expressed withdrawal will be set as censored. No data relating to the withdrawal will be utilized in the data analysis. The proportion of endpoints will be analyzed using logistic regression. Continuous secondary endpoints will be analyzed by linear regression. For analyzing missing data, model based multiple imputations will be used for both primary and secondary outcomes.
Eligible pregnant women with iron deficiency will be recruited through the Department of Obstetrics and Gynecology Department, or through health care providers that maintain obstetrical care privileges at RGH.
Treatments arms will be allocated through a blocked randomization list prepared by an online tool. Moreover, the randomization will be stratified by Hgb level in increments of 10g/L to pursue equal distribution of the two groups. The sequence list will not be accessible to the investigators. Participants will be randomly assigned to receive either IV iron isomaltoside or IV iron sucrose. IV iron sucrose is the comparator because it is currently the formulation used for IDA during second and third trimester pregnancy in Regina, Saskatchewan, Canada. Products will be stored as per the product monograph and as per requirements and guidelines set out by the Saskatchewan Health Authority.
The Saskatchewan Health Authority will ensure that the written agreement to perform trial related monitoring, audits, Research Ethics Board reviews and regulatory inspections, and provide direct access to source data and/or documents of this clinical trial, as required. Data and source documents must be readily available to the Research Ethics Board, Health Canada, Therapeutic Products Directorate, inspectors, clinical trial team members, including investigators and/or obstetrical care providers for the purposes of compliance with regulatory requirements of the clinical protocol and purposes relating to treatment, care and follow up of adverse drug reactions or by means of trace back/lookback as required. Source data and documentation include patient records whether hard copy or electronic, blood work, appointment dates and times, test and procedure results relating to this clinical trial. All source documents must be accessible during the clinical trial period and after the clinical trial has completed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Iron Deficiency Anaemia in Childbirth
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
IDA is associated with poor neonatal outcomes and maternal morbidity. This clinical trial will compare IV iron isomaltoside to IV iron sucrose for correction of IDA, along with the potential impacts to the patient: physical, emotional and convenience of attending, receiving and follow up appointments associated with iron infusion. The study will also take into consideration the financial and resource impacts to the healthcare system, and to the patient, and determine the validity of using iron isomaltoside and iron sucrose in second and third trimester pregnancy.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Iron Isomaltoside/ferric derisomaltose
route: intravenous Dosage: 1000-1500 mg (100mg/mL), max dose 20mg/kg Frequency: max dose 1000 mg, if further doses required, must receive dosage divided Duration: one infusion or two infusions (dose dependent)
Group Type
ACTIVE_COMPARATOR
Iron Isomaltoside 1000, ferric derisomaltose
Intervention Type
DRUG
iron isomaltoside 20 mg/mL
Iron Sucrose
Route: Intravenous Dosage: 100 mg/mL (maximum 300 mg per dose) Frequency: up to 3 doses per week or 1000 mg per week maximum Duration: until iron needs reached by simplified table
Group Type
ACTIVE_COMPARATOR
Iron sucrose
Intervention Type
DRUG
iron sucrose 100 mg/mL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Iron Isomaltoside 1000, ferric derisomaltose
iron isomaltoside 20 mg/mL
Intervention Type
DRUG
Iron sucrose
iron sucrose 100 mg/mL
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Monoferric DIN 22477777
iron sucrose DIN 02502917
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years of age and over
* Pregnancy with Gestational age ≥13 weeks
* Iron deficiency anemia defined as:
* Hemoglobin less than or equal to 110g/L and
* Serum ferritin less than 30ng/mL or
* Iron Saturation (Iron/TIBC) less than 20%
* Willing to participate and attend all planned follow up visits
* Willing to sign informed consent form
* Willing to attend appointments for iron infusion and follow up visits
* Willing to attend all planned bloodwork appointments
* Pregnancy with Gestational age ≥13 weeks
* Iron deficiency anemia defined as:
* Hemoglobin less than or equal to 110g/L and
* Serum ferritin less than 30ng/mL or
* Iron Saturation (Iron/TIBC) less than 20%
* Willing to participate and attend all planned follow up visits
* Willing to sign informed consent form
* Willing to attend appointments for iron infusion and follow up visits
* Willing to attend all planned bloodwork appointments
Exclusion Criteria
* Pregnancy GA less than 13 weeks
* History of anemia caused by thalassemia or other haematologic disorder other than iron deficiency anemia ,
* Known serious hypersensitivity to other parental iron products
* Iron overload or disturbances in utilization of iron (i.e, haemochromatosis and haemosiderosis)
* Decompensated liver cirrhosis or active hepatitis
* History of multiple allergies
* Active acute or chronic infections
* Treated with IV iron products or blood transfusion within 4 weeks prior to inclusion
* Current participation in any other interventional trial
* Multiple gestation pregnancy
* Significant comorbidities (asthma requiring daily therapy or other lung diseases)
* Heart disease
* Kidney disease
* Rheumatologic disease
* Cancer
* Known hypersensitivity to iron sucrose or any excipients
* Known hypersensitivity to iron isomaltoside or any excipients.
* History of anemia caused by thalassemia or other haematologic disorder other than iron deficiency anemia ,
* Known serious hypersensitivity to other parental iron products
* Iron overload or disturbances in utilization of iron (i.e, haemochromatosis and haemosiderosis)
* Decompensated liver cirrhosis or active hepatitis
* History of multiple allergies
* Active acute or chronic infections
* Treated with IV iron products or blood transfusion within 4 weeks prior to inclusion
* Current participation in any other interventional trial
* Multiple gestation pregnancy
* Significant comorbidities (asthma requiring daily therapy or other lung diseases)
* Heart disease
* Kidney disease
* Rheumatologic disease
* Cancer
* Known hypersensitivity to iron sucrose or any excipients
* Known hypersensitivity to iron isomaltoside or any excipients.
Minimum Eligible Age
18 Years
Maximum Eligible Age
50 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Saskatchewan Centre for Patient-Oriented Research
OTHER
Sponsor Role
collaborator
Saskatchewan Health Authority - Regina Area
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ryan Lett
Physician Lead Patient Blood Management Department
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ryan Lett, MD, FRCPC
Role: PRINCIPAL_INVESTIGATOR
Saskatchewan Health Authority - Regina Area
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Regina General Hospital
Regina, Saskatchewan, Canada
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Canada
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Pavord S, Daru J, Prasannan N, Robinson S, Stanworth S, Girling J; BSH Committee. UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2020 Mar;188(6):819-830. doi: 10.1111/bjh.16221. Epub 2019 Oct 2. No abstract available.
Reference Type
BACKGROUND
Wesstrom J. Safety of intravenous iron isomaltoside for iron deficiency and iron deficiency anemia in pregnancy. Arch Gynecol Obstet. 2020 May;301(5):1127-1131. doi: 10.1007/s00404-020-05509-2. Epub 2020 Apr 8.
Reference Type
BACKGROUND
Congdon EL, Westerlund A, Algarin CR, Peirano PD, Gregas M, Lozoff B, Nelson CA. Iron deficiency in infancy is associated with altered neural correlates of recognition memory at 10 years. J Pediatr. 2012 Jun;160(6):1027-33. doi: 10.1016/j.jpeds.2011.12.011. Epub 2012 Jan 11.
Reference Type
BACKGROUND
Pollock RF, Muduma G. A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000. Clinicoecon Outcomes Res. 2017 Aug 10;9:475-483. doi: 10.2147/CEOR.S139525. eCollection 2017.
Reference Type
BACKGROUND
Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J. Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: a randomized controlled trial. Vox Sang. 2017 Apr;112(3):219-228. doi: 10.1111/vox.12477. Epub 2017 Feb 15.
Reference Type
BACKGROUND
Khalafallah AA, Dennis AE, Ogden K, Robertson I, Charlton RH, Bellette JM, Shady JL, Blesingk N, Ball M. Three-year follow-up of a randomised clinical trial of intravenous versus oral iron for anaemia in pregnancy. BMJ Open. 2012 Oct 18;2(5):e000998. doi: 10.1136/bmjopen-2012-000998. Print 2012.
Reference Type
BACKGROUND
Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed., American Psychiatric Association, 2013. doi.org.db29.linccweb.org/10.1176/ appi.
Reference Type
BACKGROUND
Duley L, Uhm S, Oliver S; Preterm Birth Priority Setting Partnership Steering Group. Top 15 UK research priorities for preterm birth. Lancet. 2014 Jun 14;383(9934):2041-2042. doi: 10.1016/S0140-6736(14)60989-2. No abstract available.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HC6-024-c260086 SHA REB-21-64
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women
NCT06911034
COMPLETED
PHASE4
Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
NCT01290315
COMPLETED
PHASE2
Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)
NCT00982007
COMPLETED
PHASE3
Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia
NCT04253626
COMPLETED
PHASE3
Effect of Lactoferrin Versus Intravenous Iron Sucrose in Treatment of Anemia
NCT05921968
UNKNOWN
PHASE4
Early Antenatal Support for Iron Deficiency Anemia
NCT04278651
RECRUITING
PHASE4
Substitution of the Normal Levels of Iron and Hemoglobin in Pregnant Women With Iron Supplement
NCT02957643
COMPLETED
PHASE1/PHASE2
A Comparison Between Intravenous Iron Sucrose to Its Combination With Oral Iron Supplements for the Treatment of Postpartum Anemia
NCT02458625
COMPLETED
NA
Single Dose Intravenous Iron Isomaltoside in Combination With Oral Iron vs Oral Iron Monotherapy in Patients With Anemia After Postpartum Haemorrhage
NCT04505514
UNKNOWN
PHASE4
Treatment of (IDA) by (FPC) Delivered Via Infusion Pump in Patients Receiving Home Infusion Therapy
NCT05110768
UNKNOWN
PHASE2
Efficacy and Safety Study of Iron Sucrose and Oral Iron Acetyl-transferrin Hydroglycerin
NCT00802139
COMPLETED
PHASE4
Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia
NCT03957057
COMPLETED
PHASE3
A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer
NCT02905539
COMPLETED
PHASE4
IV Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania
NCT02541708
UNKNOWN
PHASE3
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
NCT03893045
RECRUITING
PHASE3
Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia
NCT01984554
COMPLETED
Using Stable Iron Isotopic Techniques and Serum Hepcidin Profiles to Optimize Iron Supplementation
NCT01785407
COMPLETED
NA
Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
NCT00981045
COMPLETED
PHASE3
Treatment of Women After Severe Postpartum Haemorrhage
NCT01895205
COMPLETED
PHASE3
Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding
NCT00395993
COMPLETED
PHASE3
Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia
NCT00703937
COMPLETED
PHASE3
Efficacy Study of Intravenous Iron Preparation to Iron Deficiency Anemia
NCT02731534
COMPLETED
PHASE3
Intravenous Iron Versus Oral Iron for Severe Postpartum Anemia
NCT00660933
COMPLETED
PHASE4
Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia
NCT04968379
WITHDRAWN
PHASE2
Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia
NCT05047211
COMPLETED
PHASE4